Next Article in Journal
Dignity and Its Influencing Factors in Patients with Cancer in North China: A Cross-Sectional Study
Previous Article in Journal
Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 2
10.3747/co.26.4163
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

U.S. Prevalence of Endocrine Therapy–Naïve Locally Advanced or Metastatic Breast Cancer

by
Anthony P. Nunes
1,2,*,
C. Liang
1,
W. J. Gradishar
3,
T. Dalvi
4,
J. Lewis
5,
N. Jones
5,
E. Green
1,
M. Doherty
1 and
J.D. Seeger
1
1
Optum Epidemiology, Boston, MA, USA
2
Division of Epidemiology, Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, 368 Plantation Street, Worcester, MA 01605, USA
3
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
4
AstraZeneca, Gaithersburg, MD, USA
5
AstraZeneca, Cambridge, UK
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(2), 180-187; https://doi.org/10.3747/co.26.4163
Submission received: 5 January 2019 / Revised: 2 February 2019 / Accepted: 9 March 2019 / Published: 1 April 2019

Abstract

Background: Variations in treatment choice, or late stage at first diagnosis, mean that, despite guideline recommendations, not all patients with hormone receptor (hr)–positive locally advanced or metastatic breast cancer (la/mbca) will have received endocrine therapy before disease progression. In the present study, we aimed to estimate the proportion of women with postmenopausal hr-positive la/mbca in the United States who are endocrine therapy-naïve. Methods: Women in the Optum Electronic Health Record (ehr) database with a breast cancer (bca) diagnosis (January 2008–March 2015) were included. Patient and malignancy characteristics were identified using structured data fields and natural-language processing of free-text clinical notes. The proportion of women with postmenopausal hr-positive, human epidermal growth factor 2 (her2)–negative (or unknown) la/mbca who had not received prior endocrine therapy was determined. Results were extrapolated to the entire U.S. population using the U.S. National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Results are presented descriptively. Results: In the ehr database, 11,831 women with bca had discernible information on postmenopausal status, hr status, and disease stage. Of those women, 1923 (16.3%) had postmenopausal hr-positive, her2-negative (or unknown) la/mbca, and 70.7% of those 1923 patients (n = 1360) had not received prior endocrine therapy, accounting for 11.5% of the overall population. Extrapolating those estimates nationally suggests an annual incidence of 14,784 cases, and a 5-year limited duration prevalence of 50,638 cases. Conclusions: A substantial proportion of women with postmenopausal hr-positive la/mbca in the United States could be endocrine therapy–naïve.
Keywords: breast cancer, advanced; breast cancer, metastatic; electronic health records; endocrine therapy; hormone receptor–positive disease breast cancer, advanced; breast cancer, metastatic; electronic health records; endocrine therapy; hormone receptor–positive disease

Share and Cite

MDPI and ACS Style

Nunes, A.P.; Liang, C.; Gradishar, W.J.; Dalvi, T.; Lewis, J.; Jones, N.; Green, E.; Doherty, M.; Seeger, J.D. U.S. Prevalence of Endocrine Therapy–Naïve Locally Advanced or Metastatic Breast Cancer. Curr. Oncol. 2019, 26, 180-187. https://doi.org/10.3747/co.26.4163

AMA Style

Nunes AP, Liang C, Gradishar WJ, Dalvi T, Lewis J, Jones N, Green E, Doherty M, Seeger JD. U.S. Prevalence of Endocrine Therapy–Naïve Locally Advanced or Metastatic Breast Cancer. Current Oncology. 2019; 26(2):180-187. https://doi.org/10.3747/co.26.4163

Chicago/Turabian Style

Nunes, Anthony P., C. Liang, W. J. Gradishar, T. Dalvi, J. Lewis, N. Jones, E. Green, M. Doherty, and J.D. Seeger. 2019. "U.S. Prevalence of Endocrine Therapy–Naïve Locally Advanced or Metastatic Breast Cancer" Current Oncology 26, no. 2: 180-187. https://doi.org/10.3747/co.26.4163

APA Style

Nunes, A. P., Liang, C., Gradishar, W. J., Dalvi, T., Lewis, J., Jones, N., Green, E., Doherty, M., & Seeger, J. D. (2019). U.S. Prevalence of Endocrine Therapy–Naïve Locally Advanced or Metastatic Breast Cancer. Current Oncology, 26(2), 180-187. https://doi.org/10.3747/co.26.4163

Article Metrics

Back to TopTop